{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:00:33Z","timestamp":1789426833121,"version":"build-2803163510"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/pdm.0b013e3182a3645e","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T20:48:34Z","timestamp":1393879714000},"page":"118-125","source":"Crossref","is-referenced-by-count":11,"title":["Low Frequency of EGFR Mutations in Pleural Mesothelioma Patients, Cologne, Germany"],"prefix":"10.1097","volume":"23","author":[{"given":"Verena","family":"Schildgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona-Liza","family":"Tillmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"L\u00fcsebrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schildgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brockmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Stoelben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210126","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":". Epidermal growth factor receptor mutations in lung cancer.","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R2-6-20210126","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/bi101843s","article-title":"Polymorphism of the epidermal growth factor receptor extracellular ligand binding domain: the dimer interface depends on domain stabilization.","volume":"50","author":"Zhang","year":"2011","journal-title":"Biochemistry"},{"key":"R3-6-20210126","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7819-8-88","article-title":". Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.","volume":"8","author":"Foster","year":"2010","journal-title":"World J Surg Oncol"},{"key":"R5-6-20210126","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-3-34","article-title":"Malignant mesothelioma.","volume":"3","author":"Moore","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"R6-6-20210126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12199-007-0016-7","article-title":"Current therapies for malignant pleural mesothelioma.","volume":"13","author":"Nakano","year":"2008","journal-title":"Environ Health Prev Med"},{"key":"R7-6-20210126","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ijc.21271","article-title":". Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.","volume":"118","author":"Cortese","year":"2006","journal-title":"Int J Cancer"},{"key":"R8-6-20210126","first-page":"197","article-title":"Establishment of three novel human malignant pleural mesothelioma cell lines: morphological and cytogenetical studies and EGFR mutation status.","volume":"281A","author":"Kobayashi","year":"2008","journal-title":"Anticancer Res"},{"key":"R9-6-20210126","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/JTO.0b013e31819c8661","article-title":". Absence of mutations in the epidermal growth factor receptor (EGFR) kinase domain in patients with mesothelioma.","volume":"4","author":"Velcheti","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R10-6-20210126","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jclinpath-2011-200631","article-title":". Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma.","volume":"65","author":"Enomoto","year":"2012","journal-title":"J Clin Pathol"},{"key":"R11-6-20210126","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bcp.2011.07.073","article-title":". Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK12 as antitumor targets.","volume":"82","author":"Barbieri","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"R12-6-20210126","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2174\/156800910791054130","article-title":". Gefitinib targets EGFR dimerization and ERK12 phosphorylation to inhibit pleural mesothelioma cell proliferation.","volume":"10","author":"Favoni","year":"2010","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Applied Immunohistochemistry & Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PDM.0b013e3182a3645e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:48:28Z","timestamp":1620967708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00129039-201502000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/pdm.0b013e3182a3645e","relation":{},"ISSN":["1541-2016"],"issn-type":[{"value":"1541-2016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}